{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:23:50Z","timestamp":1784795030553,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.mcna.2024.09.011","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T12:45:42Z","timestamp":1732884342000},"page":"425-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in Diagnosis and Management of Atypical Demyelinating Diseases"],"prefix":"10.1016","volume":"109","author":[{"given":"Spencer K.","family":"Hutto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien J.","family":"Cavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mcna.2024.09.011_bib1","first-page":"e51311","article-title":"Inpatient burden of neurological disorders: a route map for allocation of resources and postgraduate training","volume":"15","author":"Dsouza","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.mcna.2024.09.011_bib2","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","article-title":"Atlas of multiple sclerosis 203: a growing global problem with widespread inequity","volume":"83","author":"Aarli","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.mcna.2024.09.011_bib3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.51.10.1249","article-title":"The 150th anniversary of the first depiction of the lesions of multiple sclerosis","volume":"51","author":"Compston","year":"1988","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mcna.2024.09.011_bib4","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mcna.2024.09.011_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2024.09.011_bib6","doi-asserted-by":"crossref","first-page":"E636","DOI":"10.1212\/NXI.0000000000000636","article-title":"An argument for broad use of high efficacy treatments in early multiple sclerosis","volume":"7","author":"Stankiewicz","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.mcna.2024.09.011_bib7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.mcna.2024.09.011_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.mcna.2024.09.011_bib9","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2024.09.011_bib10","doi-asserted-by":"crossref","first-page":"577928","DOI":"10.1016\/j.jneuroim.2022.577928","article-title":"Prevalence of iatrogenic CNS inflammation at a tertiary neuroimmunology clinic","volume":"370","author":"Kelly","year":"2022","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.mcna.2024.09.011_bib11","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/brain\/awz144","article-title":"Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines","volume":"142","author":"Filippi","year":"2019","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.mcna.2024.09.011_bib12","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"Views & reviews MRI characteristics of neuromyelitis optica spectrum disorder an international update","volume":"84","author":"Jin Kim","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.mcna.2024.09.011_bib13","first-page":"312","article-title":"MRI features of demyelinating disease associated with anti-MOG antibodies in adults","volume":"46","author":"Den\u00e8ve","year":"2019","journal-title":"J\u00a0Neuroradiol"},{"key":"10.1016\/j.mcna.2024.09.011_bib14","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2024.09.011_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2013.06.014","article-title":"Intrathecal oligoclonal IgG synthesis in multiple sclerosis","volume":"262","author":"Petzold","year":"2013","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.mcna.2024.09.011_bib16","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1474-4422(23)00148-5","article-title":"Differential diagnosis of suspected multiple sclerosis: an updated consensus approach","volume":"22","author":"Solomon","year":"2023","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.mcna.2024.09.011_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"VIEWS & REVIEWS International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2024.09.011_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1148\/rg.2018170141","article-title":"Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis","volume":"38","author":"Dutra","year":"2018","journal-title":"Radiographics"},{"key":"10.1016\/j.mcna.2024.09.011_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/B978-0-444-63432-0.00021-9","article-title":"Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders","volume":"133","author":"Hinson","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12883-014-0162-7","article-title":"Neuromyelitis optica spectrum disorders without and with autoimmune diseases","volume":"14","author":"Zhang","year":"2014","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.mcna.2024.09.011_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archneur.65.5.629","article-title":"Aquaporin-4 autoantibodies in a paraneoplastic context","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib23","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/jnnp.2007.143529","article-title":"Relapsing neuromyelitis optica: long term history and clinical predictors of death","volume":"80","author":"Cabre","year":"2009","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.mcna.2024.09.011_bib24","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2006.06.060","article-title":"Natural history of the visual impairment of relapsing neuromyelitis optica","volume":"114","author":"Merle","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mcna.2024.09.011_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.mcna.2024.09.011_bib26","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks A retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.mcna.2024.09.011_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.mcna.2024.09.011_bib28","doi-asserted-by":"crossref","first-page":"E1351","DOI":"10.1212\/WNL.0000000000012599","article-title":"CNS demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies","volume":"97","author":"Zhao-Fleming","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2024.09.011_bib29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.09.011_bib31","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.09.011_bib32","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2024.09.011_bib33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3988\/jcn.2022.18.3.280","article-title":"Clinical and radiological features of myelin oligodendrocyte glycoprotein-associated myelitis in adults","volume":"18","author":"Kim","year":"2022","journal-title":"Journal of Clinical Neurology (Korea)"},{"key":"10.1016\/j.mcna.2024.09.011_bib34","first-page":"2088","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib35","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.msard.2021.102742","article-title":"What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)","volume":"49","author":"Carnero Contentti","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.mcna.2024.09.011_bib36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib37","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1016\/j.mcna.2024.09.011_bib38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"3","key":"10.1016\/j.mcna.2024.09.011_bib39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib40","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.26858","article-title":"Time to disability milestones and annualized relapse rates in NMOSD and MOGAD","volume":"95","author":"Duchow","year":"2024","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib41","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib42","first-page":"e1858","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology. NLM (Medline)"},{"key":"10.1016\/j.mcna.2024.09.011_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.mcna.2024.09.011_bib44","doi-asserted-by":"crossref","first-page":"e055392","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.mcna.2024.09.011_bib45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajo.2023.02.013","article-title":"Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks","volume":"252","author":"Chen","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.mcna.2024.09.011_bib46","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2024.09.011_bib47","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pediatrneurol.2019.06.017","article-title":"Acute disseminated encephalomyelitis in children: an updated review based on current diagnostic criteria","volume":"100","author":"Cole","year":"2019","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib49","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/cid\/ciw607","article-title":"Acute demyelinating events following vaccines: a case-centered analysis","volume":"63","author":"Baxter","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.mcna.2024.09.011_bib50","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1212\/NXI.0000000000001080","article-title":"Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19: systematic review and meta-synthesis","volume":"8","author":"Manzano","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.mcna.2024.09.011_bib51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.braindev.2019.02.011","article-title":"Clinical time course of pediatric acute disseminated encephalomyelitis","volume":"41","author":"Nishiyama","year":"2019","journal-title":"Brain Dev"},{"key":"10.1016\/j.mcna.2024.09.011_bib52","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejpn.2016.08.014","article-title":"Evolution of MRI abnormalities in paediatric acute disseminated encephalomyelitis","volume":"21","author":"Wong","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"issue":"22","key":"10.1016\/j.mcna.2024.09.011_bib53","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1212\/WNL.0000000000002723","article-title":"Acute disseminated encephalomyelitis in 228 patients A retrospective, multicenter US study","volume":"86","author":"Koelman","year":"2016","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.mcna.2024.09.011_bib54","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.mcna.2024.09.011_bib55","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.mcna.2024.09.011_bib56","doi-asserted-by":"crossref","first-page":"104008","DOI":"10.1016\/j.msard.2022.104008","article-title":"Oligoclonal bands, age 11\u201317 years, occipital lesion, and female sex differentiate pediatric multiple sclerosis from acute disseminated encephalomyelitis: a nationwide cohort study","volume":"66","author":"Boesen","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.mcna.2024.09.011_bib57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pediatrneurol.2019.03.002","article-title":"Diagnostic value of oligoclonal bands in children: a nationwide population-based cohort study","volume":"97","author":"Boesen","year":"2019","journal-title":"Pediatr Neurol"},{"issue":"6","key":"10.1016\/j.mcna.2024.09.011_bib58","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1212\/WNL.54.6.1370","article-title":"Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin","volume":"54","author":"Sahlas","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mcna.2024.09.011_bib59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-510X(99)00072-6","article-title":"Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis","volume":"165","author":"Pradhan","year":"1999","journal-title":"J\u00a0Neurol Sci"},{"issue":"2","key":"10.1016\/j.mcna.2024.09.011_bib60","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0887-8994(99)00042-9","article-title":"Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis","volume":"21","author":"Nishikawa","year":"1999","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib61","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The lenercept multiple sclerosis study group and the university of British columbia MS\/MRI analysis group","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2024.09.011_bib62","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.mcna.2024.09.011_bib63","doi-asserted-by":"crossref","first-page":"577587","DOI":"10.1016\/j.jneuroim.2021.577587","article-title":"CNS demyelination with TNF\u03b1 inhibitor exposure: a retrospective cohort study","volume":"356","author":"Hutto","year":"2021","journal-title":"J\u00a0Neuroimmunol"},{"issue":"16","key":"10.1016\/j.mcna.2024.09.011_bib64","first-page":"754","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology Lippincott Williams and Wilkins"},{"issue":"8","key":"10.1016\/j.mcna.2024.09.011_bib65","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/1352458519828601","article-title":"Iatrogenic CNS demyelination in the era of modern biologics","volume":"25","author":"Kumar","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.mcna.2024.09.011_bib66","article-title":"Central nervous system demyelination related to tumour necrosis factor alpha inhibitor","volume":"8","author":"Chey","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3","key":"10.1016\/j.mcna.2024.09.011_bib67","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/1352458514564490","article-title":"A\u00a0systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.mcna.2024.09.011_bib68","first-page":"62","article-title":"Myelitis and other autoimmune myelopathies","volume":"27","author":"Chiriboga","year":"2021","journal-title":"Continuum (Minneap Minn)"},{"issue":"9","key":"10.1016\/j.mcna.2024.09.011_bib69","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2024.09.011_bib70","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.mcna.2024.09.011_bib71","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000528556","article-title":"Therapeutic plasmapheresis: a revision of literature","volume":"48","author":"Altobelli","year":"2023","journal-title":"Kidney Blood Press Res"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524001263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524001263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T12:14:08Z","timestamp":1749298448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712524001263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0025712524001263"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2024.09.011","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Diagnosis and Management of Atypical Demyelinating Diseases","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2024.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}